化合物6877002 | 433249-94-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 化合物6877002
• 英文名称: TRAF-STOP inhibitor 6877002
• 英文别名: (E)-3-(2,5-dimethylanilino)-1-phenylprop-2-en-1-one
• CAS: 433249-94-6
• 化学式: C₁₇H₁₇NO
• 分子量: 251.32
• InChiKey: SARYOFMRLSHZFE-ZHACJKMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• THERAPEUTIC TARGETING OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK4) IN CANCERS CHARACTERIZED BY REARRANGEMENTS IN THE MIXED LINEAGE LEUKEMIA GENE (MLL-r)
  申请人：Northwestern University

  公开号：US20170305901A1

  公开（公告）日：2017-10-26

  Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).

  揭示了治疗与混合系谱白血病基因（MLL-r）重排相关的癌症的方法，包括MLL-r白血病。这些方法通常包括给予治疗量的一个或多个治疗剂，其抑制白介素-1信号通路的一个或多个成员的生物活性，例如白介素-1受体相关激酶4（IRAK4）的抑制剂。
• Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
  申请人：Northwestern University

  公开号：US10059708B2

  公开（公告）日：2018-08-28

  Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).

  所公开的是治疗与混合系白血病基因（MLL-r）重排相关的癌症（包括 MLL-r 白血病）的方法。这些方法通常包括施用治疗量的一种或多种治疗剂，这些治疗剂可抑制白细胞介素-1 信号通路的一个或多个成员的生物活性，如白细胞介素-1 受体相关激酶 4（IRAK4）的抑制剂。
• Compounds and compositions for treating conditions associated with NLRP activity
  申请人：NOVARTIS INFLAMMASOME RESEARCH, INC.

  公开号：US10654816B2

  公开（公告）日：2020-05-19

  In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

  在一个方面，式 AA 的化合物或其药学上可接受的盐是其特征： 或其药学上可接受的盐，其中式 A 中所示的变量可以如本文中任何地方所定义的那样。
• Gastrointestinal tract detection methods, devices and systems
  申请人：Progenity Inc.

  公开号：US10610104B2

  公开（公告）日：2020-04-07

  The present disclosure relates to gastrointestinal (GI) tract detection methods, devices and systems.

  本公开涉及胃肠道（GI）检测方法、装置和系统。
• Therapeutic targeting of interleukin-1 receptor-associated kinase 4 (IRAK4) in cancers characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
  申请人：Northwestern University

  公开号：US10640502B2

  公开（公告）日：2020-05-05

  Disclosed are methods for treating cancers associated with rearrangements in the mixed lineage leukemia gene (MLL-r), including MLL-r leukemia. The methods typically include administering a therapeutic amount of one or more therapeutic agents that inhibit the biological activity of one or more members of the interleukin-1 signaling pathway such inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4).

  所公开的是治疗与混合系白血病基因（MLL-r）重排相关的癌症（包括 MLL-r 白血病）的方法。这些方法通常包括施用治疗量的一种或多种治疗剂，这些治疗剂可抑制白细胞介素-1 信号通路的一个或多个成员的生物活性，如白细胞介素-1 受体相关激酶 4（IRAK4）的抑制剂。